Dupixent® (dupilumab) Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms Presented for the First Time at Scientific Meetings |
| October 26, 2020 | October 2020 Bond Updates |
|
TARRYTOWN, N.Y. and PARIS, Oct. 26, 2020 /PRNewswire/ -- First Phase 3 trial in eosinophilic esophagitis (EoE) to show a biologic medicine significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older New late-breaking... |
| View more at: https://www.prnewswire.com:443/news-releases/dupixent-dupilumab-late-breaking-pivotal-data-showing-significant-improvement-in-eosinophilic-esophagitis-signs-and-symptoms-presented-for-the-first-time-at-scientific-meetings-301159325.html |
| Related News |
|